Go to content

Publications

460 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. GVS advice solriamfetol (Sunosi®) for the treatment of narcolepsy or obstructive sleep apnoea

    The National Health Care Institute has completed its assessment whether the medicinal product solriamfetol (Sunosi®) can be ...

    Report | 23-12-2022

  2. Appendix to guideline for cost-effectiveness models in R - packages and versions

    Appendix to guideline for cost-effectiveness models in R - packages and versions.

    Publication | 15-12-2022

  3. Guideline for building cost-effectiveness models in R

    Guideline for building cost-effectiveness models in R.

    Publication | 15-12-2022

  4. GVS advice fostamatinib (Tavlesse®) for the treatment of chronic immune thrombocytopenia

    The National Health Care Institute has completed its assessment whether the medicinal product fostamatinib (Tavlesse®) is ...

    Report | 06-12-2022

  5. GVS advice doxylamine succinate/pyridoxine hydrochloride (Xonvea®) for the treatment of nausea and vomiting during pregnancy

    The National Health Care Institute has completed its assessment whether the medicinal product doxylamine succinate/pyridoxine ...

    Report | 29-11-2022

  6. GVS advice baloxavir marboxil (Xofluza®)

    The National Health Care Institute has completed its assessment whether the product baloxavir marboxil (Xofluza®) is ...

    Report | 24-11-2022

  7. GVS advice on liraglutide (Saxenda®) and naltrexon/ bupropion (Mysimba®) extension of further conditions

    The National Health Care Institute has completed its assessment whether the List 2 conditions for liraglutide (Saxenda®) and ...

    Report | 23-11-2022

  8. GVS advice to include house dust mite extract 300 IR HDM (Actair®)

    The National Health Care Institute has completed its assessment whether house dust mite extract 300 IR HDM (Actair®) can be ...

    Report | 10-11-2022

  9. Package advice pralsetinib (Gavreto®) for the treatment of non-small cell lung carcinoma (NSCLC)

    The National Health Care Insititue has completed its assessment whether pralsetinib (Gavreto®) can be included in the basic ...

    Report | 10-11-2022

  10. Progress of the conditional inclusion process for rhPTH 1-84 (Natpar®)

    The National Health Care Institute advises the Director of Pharmaceuticals and Medical Technology at the Ministry of Health, ...

    Report | 02-11-2022

Go to